Executive Summary Biopure Corporation was established in 1984 and is a privately owned pharmaceutical firm. They are trying to launch two new products: Hemopure (human market) and Oxyglobin (veterinary market). They are the only company aggressively engaged in the development of blood substitutes for the vet market. Biopure has invested $200M in the development of said blood substitutes. They currently don’t have any revenues with little to no debt and financing of $50M to support these operations
Premium Health care Net present value Medicine
Biopure Case Analysis Group 1‚ Section B The analysis deals with the Target Markets and their different segments for the two products of Biopure Corporation‚ namely Oxyglobin and Hemopure. Oxyglobin -‐ Used as a substitute for blood transfusion in dogs. -‐ Target market is 30% of all the
Premium
The Potential Market for Apple iPad in the UK Table of contents 1.0 Introduction 3 2.0 Creative thinking 3 3.0 Recommendations for successfully marketing iPad in the UK 3 4.0 Conclusion 4 References 5 1.0 Introduction After iSlate and iGuide‚ iPad as another tablet-shaped computer was launched by Apple. The various applications of the iPad are very attractive for customers‚ but it also has some shortcomings including high price and the same user interface as iPhone. The
Premium Marketing
1. a) Potential market for Humans To accurately calculate the number of units that would be required per year in the human market‚ we first estimated the total number of patients that would require RBC transfusions divided in three main groups: Elective and emergency surgeries: The current market is of 7.9 million units‚ but there is also an unserved market of borderline transfusions that would require an additional 1.5 million units (1 million surgeries with requirements of 1-2 units / surgery)
Premium Blood Organ transplant Blood transfusion
Decision Sheet – Biopure Corporation Marketing Objective – Whether to launch Oxyglobin now or delay it till the approval of Hemopure. If yes‚ then devise a marketing plan for Oxyglobin. Options – 1. Launch Oxyglobin in the market immediately. 2. Defer the launch of Oxyglobin now till Hemopure release. Recommendation – Biopure Corporation should immediately launch Oxyglobin priced at $200. Rationale – Applying SWOT Analysis to the situation: Strengths 1. FDA approval has already come
Premium Blood Blood transfusion Marketing
INTRODUCTION The purpose of this term paper is to determine the potential and limits of the carbon market integration . In this paper we will discuss shortly about the political economy of the carbon trading systems and top-down and bottom-up integration scenarios towards a global carbon market. Cap-and-trade systems establish property rights to emissions‚ allocate them to actors that are included in the system‚ create a market in which those actors can trade these property rights and‚
Premium Emissions trading Kyoto Protocol
Carl Rausch President and CEO of Biopure Corporation FROM: Hoang‚ Ann and Mishra‚ Ravi RE: Whether and When to Launch Oxyglobin Biopure needs to determine the best course of action to launch two new products‚ Oxyglobin a blood substitute for the veterinary market and Hemopure a blood substitute for the human market. Oxyglobin has been approved for commercial use and is ready for launch while Hemopure is expected to be FDA approved within two years. Biopure needs to decide whether and when
Premium Blood Blood transfusion Marketing
how it helps in the recording process. Explain what a ledger is and how it helps in the recording process. Explain what posting is and how it helps in the recording process. Prepare a trial balance and explain its purposes. Questions 1 Brief Exercises Exercises 1 A Problems B Problems 2. 2‚ 3‚ 4‚ 5‚ 6‚ 7‚ 8‚ 9‚ 14 1‚ 2‚ 5 2‚ 4‚ 6‚ 7‚ 14 1A‚ 2A‚ 3A‚ 5A 1B‚ 2B‚ 3B‚ 5B 3. 10‚ 19 4 6‚ 7 4. 11‚ 12‚ 13‚ 14‚ 16 3‚ 6 3‚ 5‚ 6‚ 7 10‚ 11‚ 12 1A‚ 2A‚ 3A‚ 5A 1B‚ 2B
Premium Accounts receivable Double-entry bookkeeping system
Biopure Case Study Executive Summary * Biopure Corporation developed two new products to enter into the field of blood substitutes: Hemopure‚ directed to the human market and Oxyglobin‚ for the veterinary market. Through the end of 1997 no blood substitute had received approval for use anywhere in the world. * What distinguishes both products from other “hemoglobin-based” blood substitutes is the fact that they are “bovine-sourced” as opposed to “human-sourced”‚ i.e. they are derived from
Free Blood Blood transfusion
CHAPTER 2 EXERCISES & PROBLEMS SOLUTIONS E2.1. Category Financial Statement(s) Cash…………………………………………… A BS Accounts payable…………….……………….. L BS Common stock………………………………… OE BS Depreciation expense………………………….. E IS Net sales……………………………………….. R IS Income tax expense……………………………. E IS Short term investments………………………... A BS Gain on sale of land……………………………. G IS Retained earnings……………………………… OE BS Dividends payable……………………………
Premium Generally Accepted Accounting Principles Balance sheet Accounts receivable